Academic Journal
The effects of a growth hormone-releasing hormone antagonist and a gastrin-releasing peptide antagonist on intimal hyperplasia of the carotid artery after balloon injury in a diabetic rat model☆
| Title: | The effects of a growth hormone-releasing hormone antagonist and a gastrin-releasing peptide antagonist on intimal hyperplasia of the carotid artery after balloon injury in a diabetic rat model☆ |
|---|---|
| Authors: | John C. Moscona, Matthew N. Peters, Andrew V. Schally, Sudesh Srivastav, Patrice Delafontaine, Anand Irimpen |
| Source: | Artery Research, Vol 19 (2017) |
| Publisher Information: | BMC, 2017. |
| Publication Year: | 2017 |
| Collection: | LCC:Specialties of internal medicine LCC:Diseases of the circulatory (Cardiovascular) system |
| Subject Terms: | Neointimal hyperplasia, Growth hormone-releasing hormone antagonist, Gastrin-releasing peptide antagonist, Arterial restenosis, Diabetes mellitus, Specialties of internal medicine, RC581-951, Diseases of the circulatory (Cardiovascular) system, RC666-701 |
| More Details: | Introduction: Arterial restenosis after angioplasty/stenting has hindered coronary artery disease treatment, especially in diabetics. We theorized that gastrin-releasing peptide (GRP) antagonists and growth hormone-releasing hormone (GHRH) antagonists might decrease neointimal hyperplasia and restenosis in diabetic rats after common carotid arterial balloon injury. Methods: Two separate experiments were conducted to test the effects of a GRP antagonist (RC-3095) and a GHRH antagonist (MZ-4-71) on vascular smooth muscle (VSM) growth. In a preliminary in vitro experiment non-injured human aortic vascular smooth muscle (VSM) proliferation was compared between growth media and control. In a second in vivo experiment, intimal and medial area, intima/media ratio (IM) and percent stenosis were compared between injured carotid arteries in twelve Zucker type II obese rats treated with subcutaneously injected RC-3095, MZ-4-71, or control media. Results: In the in vitro experiment, decreased VSM cell growth was observed in GRP antagonist (p < 0.05) and GHRH antagonist groups (p < 0.05) compared to the control group. In the in vivo experiment, the GRP antagonist group had a decreased IM ratio (1.63 ± 0.41, p < 0.05) and an increased area of stenosis (98.78% ± 1.48 p = NS) compared to control (2.38 ± 1.09) while the GHRH antagonist group had decreased IM ratio (1.33 ± 0.58 SD, p < 0.05) and percent area of stenosis (78.84% ± 24.97, p < 0.05) compared to control (2.38 ± 1.09). Conclusions: The significant decrease in both IM ratio and percent area of stenosis in the GHRH antagonist group supports the hypothesis that this peptide may reduce neointimal hyperplasia and restenosis. |
| Document Type: | article |
| File Description: | electronic resource |
| Language: | English |
| ISSN: | 12592498 1876-4401 |
| Relation: | https://www.atlantis-press.com/article/125924982/view; https://doaj.org/toc/1876-4401 |
| DOI: | 10.1016/j.artres.2017.06.006 |
| Access URL: | https://doaj.org/article/f1db94ed0ec144cdb68ad211436aa838 |
| Accession Number: | edsdoj.f1db94ed0ec144cdb68ad211436aa838 |
| Database: | Directory of Open Access Journals |
| ISSN: | 12592498 18764401 |
|---|---|
| DOI: | 10.1016/j.artres.2017.06.006 |
| Published in: | Artery Research |
| Language: | English |